Results 151 to 160 of about 551,808 (299)
FDA enforcement manual (Thompson FDA).
Thompson's FDA enforcement manual is the comprehensive online resource guide to the Food and Drug Administration's enforcement authority, policies and practices for the drug, medical device, biologics, food, cosmetics and tobacco industries.
core
FDA roadmap to reducing animal testing: a regulatory and scientific paradigm shift in nonclinical safety assessment. [PDF]
Lei Y, Tuan RS, Li ZA.
europepmc +1 more source
We developed a nanoparticle named OAF, which simultaneously targeted to both the brain and liver via the transferrin receptor 1 (TfR1) receptor, promoting lipoprotein receptor‐related protein 1 (LRP1) expression to enhance amyloid‐beta (Aβ) clearance. In AD mice model, OAF significantly reduced Aβ deposition and cognitive impairment, while a mitigating
Wenshuai Gong +8 more
wiley +1 more source
FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
Teresa Krakauer Department of Immunology, Molecular Translational Sciences Division, United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, USA Abstract: Immunostimulating staphylococcal enterotoxin B (SEB)
Krakauer T
core
Access to orphan drugs in adults with inherited metabolic diseases in Switzerland: a single-center retrospective cohort study. [PDF]
Antoni G +4 more
europepmc +1 more source
ABSTRACT While targeted therapies have improved outcomes in lung adenocarcinoma (LUAD), many patients still lack targetable mutations. Here, we identified alpha‐L‐fucosidase 2 (FUCA2) as a crucial driver of LUAD by preventing cellular senescence. Mechanistically, through the restriction of fucosyltransferase 3 (FUT3)‐mediated α‐1,3‐fucosylation of ...
Lu Chen +18 more
wiley +1 more source
Phage Therapy: Concept to Cure
Eric Christopher Keen
doaj +1 more source
This study explores the opposing effects of the mGluR2 and mGluR3 receptors on amyloid precursor protein processing. mGluR2 promotes amyloidogenic cleavage, while mGluR3 favors non‐amyloidogenic pathways. Using a brain‐penetrant nanobody as a mGluR2 positive allosteric modulator, the study uncovers how its chronic activation aggravates amyloid‐β burden
Pierre‐André Lafon +21 more
wiley +1 more source
Expert perspectives on the ecosystem of medical AI oversight in the GenAI era. [PDF]
Gilbert S, Dai T.
europepmc +1 more source

